The Mechanisms of Aspirin Therapy in Sepsis [MATHS] trial

Phase 2

• Conditions: sepsis; Infection - Studies of infection and infectious agents; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12616001377426
• Lead Sponsor: Townsville Hospital and Health Service

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-10-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 135

Inclusion Criteria

Sepsis according to Sepsis-3 consensus definition

Exclusion Criteria

Regular aspirin for myocardial ischaemia.
Aspirin/NSAID in last 7 days
Hypersensitivity to aspirin/NSAIDs
Platelet count <100,000 x10^9/L
Active bleeding (trauma, gastrointestinal, or intracranial)
Life expectancy less than 24 hours

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Measurement of the effect of low-dose aspirin on immunological pathways caused by ATL. Will be assessed using blood tests and subsequent assays on expression patterns of the above molecule taken at below specified timepoints. [Baseline, at 1 hour, at 4 hours, at 8 hours, at 24 hours, and at 48 hours post intervention];Measurement of the effect of low-dose aspirin on immunological pathways caused by NF-kB. Will be assessed using blood tests and subsequent assays on expression patterns of the above molecule taken at below specified timepoints. [Baseline, at 1 hour, at 4 hours, at 8 hours, at 24 hours, and at 48 hours post intervention]